MEMO FROM THE FUTURE: OPHTHALMOLOGY INNOVATIVE FOUNDERS

The Gold Rush & the Survivors — June 2030

CONFIDENTIAL | The 2030 Report GLOBAL INTELLIGENCE CRISIS SERIES

EXECUTIVE SUMMARY

By June 2030, the ophthalmology AI/innovation space has undergone a classic venture capital arc: explosive hype (2027-2028), crash (2029), and consolidation (2030). Of the 80+ ophthalmology-focused startups founded between 2025-2028, fewer than 15 have reached substantial scale. The winners are those that:

1. Built defensible IP in AI diagnostic interpretation (FDA/CE cleared systems)
2. Achieved early adoption by large group practices or hospital systems
3. Positioned for US (not international) first launch
4. Focused on specific, high-value clinical problems (not "general" ophthalmology AI)
5. Maintained capital discipline to survive the 2029 funding crunch

This memo focuses on the surviving cohort and the strategic landscape for ophthalmology founders in June 2030 and beyond.

I. THE FUNDING BOOM & BUST CYCLE (2025-2030)

The Hype Phase (2025-2028)

Following successful FDA clearance of Google's diabetic retinopathy AI (DeepMind 2027) and others, ophthalmology AI became a venture capital darling:

Funding trends: - 2025: $120M raised by ophthalmology startups (US) - 2026: $340M raised - 2027: $680M raised (peak mania) - 2028: $520M raised (slight decline, but still robust) - 2029: $140M raised (crash; many investors fled healthcare AI)

Funded companies (sample of major rounds, 2027-2028): - Autonomous Health: Series B, $150M (February 2028, valued $800M) - Retinal AI: Series A, $85M (June 2027) - EyeThink: Series B, $120M (August 2028) - Comet AI: Series B, $90M (March 2028) - Others: 30+ companies raised $50M-$150M per round

The Crash Phase (2029)

By late 2028, venture investors realized: - Regulatory pathways were slower than expected (FDA De Novo reviews 18-24 months) - Customer acquisition was harder (large groups didn't immediately adopt new AI systems) - Reimbursement for AI diagnostic services was uncertain - Many AI companies were competing for the same diagnostic indications (overcrowding)

2029 funding crunch: - Investor appetite evaporated; few new rounds closed - 15-20 startups ran out of capital and shut down or merged - "Walking dead" status: 20-30 startups with 12-18 months of runway, seeking acquirers or down-round financing - Pressure on later-stage companies (Series B/C) to show traction or face significant down-rounds

Notable failures/struggles (2029-2030): - Comet AI: Series C down-round from $300M valuation to $120M (April 2029) - RetinalGenix: Acquired by Alcon at distressed valuation (March 2029), implied $180M valuation (down 65% from 2028 estimate) - 5+ other companies acquired or merged

II. THE SURVIVORS: DEFENSIBLE OPPORTUNITIES & WINNING STRATEGIES

Category 1: FDA-Cleared Autonomous Diagnostic Systems

The winners: - Companies that achieved FDA De Novo clearance or 510(k) approval for autonomous AI diagnostic systems - These companies could charge payers/practices directly for a "diagnostic service" - Regulatory approval created moat against competition

Successful companies in this category:

1. Autonomous Health (formerly Autonomous.ai)
2. Founded: 2018
3. Focus: Comprehensive AI diagnostic EHR for ophthalmology
4. FDA Status: De Novo cleared for diabetic retinopathy, glaucoma screening (2028-2029)
5. Clinical Evidence: Published RCT showing 98.2% sensitivity for DR screening
6. Business Model: SaaS for large group practices; per-case fees for screening centers
7. Status (June 2030): Profitable or near-breakeven; ~$40M run-rate revenue estimate

8. Valuation trajectory: $800M (2028 Series B) → $1.8-2.4B (2030 projected Series C/D)

9. Retinal AI (formerly RetinalAI Analytics)

10. Founded: 2019
11. Focus: AMD, DME, RVO AI interpretation; anti-VEGF treatment optimization
12. FDA Status: 510(k) cleared for retinal disease diagnosis (2029)
13. Business Model: Per-case licensing to practices; partnership with large groups
14. Status (June 2030): Growing revenue; ~$20M run-rate estimate

15. Trajectory: Series A $85M → Series C being negotiated (2030)

16. EyeThink

17. Founded: 2020
18. Focus: Comprehensive ophthalmic AI (retina, glaucoma, cataract planning)
19. FDA Status: Multiple 510(k) clearances (2028-2029); pursuing De Novo for comprehensive platform
20. Business Model: Embedded SaaS; licensing to surgical centers and large groups
21. Status (June 2030): Growing customer base; ~$25M run-rate revenue estimate
22. Valuation trajectory: $650M (2028) → $1.2-1.8B (2030 projected)

Why these succeeded: - Clear FDA pathway; achieved regulatory approval early - Strong clinical evidence (RCTs, published validation studies) - Large group adoption (Bausch + Lomb, J&J signed partnerships) - Reimbursement clarity (CMS, commercial payers reimbursing autonomous diagnostic services)

Category 2: AI-Powered Surgical Planning & Optimization

The opportunity: AI systems that optimize surgical outcomes (IOL selection, corneal incision planning, LASIK planning) without replacing surgeon judgment.

Successful companies:

1. RxSight (acquired by Alcon, 2029)
2. Original focus: Light-adjustable IOLs + AI optimization algorithms
3. Acquisition: Alcon acquired for estimated $280M (2029)
4. Status (June 2030): Integrated into Alcon surgical planning suite

5. Revenue trajectory: Growing through Alcon distribution

6. Omni Surgical

7. Founded: 2021
8. Focus: AI surgical decision support (which cases to do, cataract complexity triage)
9. Business Model: Licensing to surgical centers; payer/hospital partnerships
10. Status (June 2030): Series B (2029, $55M); growing traction with mega-groups

11. Estimated run-rate revenue: ~$15M

12. Comet AI (formerly Comet Therapeutics)

13. Founded: 2015
14. Focus: Cataract surgical planning + complication risk prediction
15. Challenges: Down-round (2029); slower adoption than expected
16. Status (June 2030): Seeking strategic buyer or acquisition
17. Valuation: ~$120M (down 60% from 2028 peak)

Why these worked better than pure diagnostic AI: - Surgeons valued clinical support (not replacement) - Outcomes improvement was quantifiable (fewer complications, better refractive results) - Large group adoption easier (surgery is high-margin; payers more willing to reimburse surgical optimization)

Category 3: AI-Enabled Optical Retail & Consumer Refraction

The opportunity: AI autorefraction + prescription optimization that eliminates need for in-office exams.

Key developments (2027-2030): - Warby Parker launched AI refraction smartphone app (2028); now used by 2M+ users - Zenni (online eyewear retailer) partnered with AI refraction startup (2029) - Multiple standalone AI refraction companies launched (EyeFit, VisionLabs, others)

Notable company: VisionLabs - Founded: 2020 - Focus: Smartphone-based AI refraction; prescription generation without doctor - Regulatory status: Cleared as non-medical/wellness tool (not FDA-regulated device) - Business Model: B2C (direct consumer) + B2B (retail partners, insurance companies) - Status (June 2030): ~$8M run-rate revenue; Series B (2029, $40M) - Trajectory: Fast-growing but regulatory risk (FDA may eventually regulate)

Why this category is controversial: - Disintermediated optometrists and ophthalmologists - Regulatory arbitrage: Companies claimed "wellness tools" to avoid FDA approval requirements - By June 2030, FDA began scrutiny; regulatory clarity coming 2030-2031

Outcome for founders: High growth, but regulatory risk and professional opposition make exits tricky. Acquisition by insurance companies, retail groups, or tech platforms likely.

Category 4: Teleophthalmology & Remote Diagnosis Platforms

Opportunity: Enabling AI-augmented asynchronous remote diagnosis for rural/underserved patients.

Successful company: InSight Telemedicine - Founded: 2022 - Focus: Remote AI diagnostic screening + specialist review (asynchronous) - Business Model: Per-encounter fees from payers; partnerships with government programs (rural ophthalmology) - Status (June 2030): Series A (2029, $32M); expanding rapidly - Estimated revenue: ~$12M run-rate - Why it works: Addresses rural access gap; government reimbursement for underserved areas

Why teleophthalmology survived when pure diagnostics saturated: - Addressed a real need (rural access) - Government reimbursement less competitive than commercial - Workflow integration clearer (remote diagnosis → local optometrist follow-up)

Category 5: AI for Niche/Rare Ophthalmology Diseases

The principle: Focus on rare, complex diseases where AI training data was limited but where diagnosis was difficult and specialists scarce.

Examples: - Neuro-ophthalmology AI (optic neuritis, IIH diagnosis) - Pediatric ophthalmology AI (strabismus planning, refractive error optimization) - Corneal/anterior segment disease AI

Status (June 2030): These remained early-stage (Series A or pre-seed); less hype, slower growth, but more defensible (less competition).

III. THE FAILED STRATEGIES

The "General Ophthalmology AI" Problem

Many startups tried to build "comprehensive AI for all ophthalmology" and failed because: 1. Too broad a scope (glaucoma + retina + anterior segment = three different markets) 2. Regulatory burden (multiple FDA clearances needed) 3. Customer competition (each clinical area had 3-5+ competitors) 4. Reimbursement uncertainty (payers treated different indications differently)

Failed companies (sample): - EyeKnowLogy: Ambitious comprehensive AI platform; ran out of capital 2029; acquired at distressed valuation - Medtech AI: Raised $60M; couldn't gain traction with large groups; seeking acquisition - VisionMatch: Focused on retinal imaging analysis; overcrowded market; merged with competitor (down-round)

The "International First" Mistake

Some startups pursued India, Southeast Asia, or Europe first (lower regulatory burden, perceived easier market entry): - Regulatory approval timelines were NOT shorter outside US - Payer reimbursement was LESS clear (outside US/Canada/UK/Australia) - Customer acquisition costs were HIGHER (fragmented markets) - Exit paths were LIMITED (US acquirers reluctant to acquire companies with international-first positioning)

Lesson by June 2030: US-first regulatory clearance (FDA) and US-first commercial traction became non-negotiable for successful exits.

IV. REGULATORY PATHWAYS & FDA STRATEGY (JUNE 2030)

FDA De Novo vs. 510(k) Strategy

By June 2030, clear regulatory strategy differentiated winners from losers:

De Novo pathway (for novel AI diagnostic systems): - Timeline: 18-24 months - Cost: $1.5M-3M - Burden: Extensive clinical validation, RCT data - Advantage: Creates new regulatory category; high protection against competition - Companies choosing this path: Autonomous Health, others building truly novel systems

510(k) pathway (for substantially equivalent AI systems): - Timeline: 6-12 months - Cost: $0.5M-1M - Burden: Comparative effectiveness to predicate device - Advantage: Faster approval; lower cost - Risk: Overcrowded category; limited competitive moat - Companies choosing this path: EyeThink, Retinal AI, others building incremental improvements

Regulatory arbitrage (non-medical claims): - Timeline: 0-3 months - Cost: Minimal - Burden: Compliance with FTC (not FDA) - Advantage: Fastest to market - Risk: Regulatory backlash; potential FDA enforcement - Companies attempting this: AI refraction startups (VisionLabs, EyeFit)

By June 2030, FDA was increasing scrutiny on regulatory arbitrage claims. Companies claiming "wellness" vs. "medical" faced increasing FDA pressure to clarify status.

V. FUNDING & CAPITAL STRATEGIES (LESSONS FROM 2027-2030)

What Founders Learned the Hard Way

Lesson 1: Burn rate discipline - Early-stage companies that burned $2M+/month didn't survive the 2029 crunch - Survivors maintained 24-36 month runway, even at slower growth

Lesson 2: Clinical evidence requirements - Published RCT data became essential for Series B financing - Companies that relied on internal validation data struggled in 2029

Lesson 3: FDA clearance before aggressive scaling - Companies that achieved regulatory approval before rapid hiring/sales survived better - Those that scaled before approval faced 2-3 year delays and capital requirements

Lesson 4: Customer diversification - Dependency on 1-2 major customers (large group, hospital system) created acquisition risk - Diversified customer base (payers, retail, small practices) reduced risk

Lesson 5: Reimbursement clarity - Companies with clear payer reimbursement pathways fundraised easier - Those with uncertain reimbursement faced discount rates on valuations

Surviving Founders' Fundraising Strategies (2029-2030)

By June 2030, surviving founders used: - Strategic partnerships with large groups (Bausch + Lomb, J&J) to validate and fund development - Government contracts (rural telehealth) to create revenue and reduce cash burn - Acquirer partnerships (building IP for potential acquirer, creating exit optionality) - Focused investor base (specialized healthcare VCs, corporate VCs from large medical device companies)

VI. MARKET SIZE & OPPORTUNITY ASSESSMENT (JUNE 2030)

Addressable Market by Clinical Indication

Diabetic Retinopathy Screening: - US diabetic population: 37M - Annual screening need: 12-15M (unscreened) - Revenue per screening (AI-assisted): $25-50 - TAM: $300-750M annually (US only) - Status (June 2030): Largely captured by FDA-cleared systems; market consolidating around 3-5 dominant players

Glaucoma Screening: - US glaucoma suspects: 5-7M - Annual screening need: 2-3M - Revenue per screening: $40-80 - TAM: $80-240M annually - Status (June 2030): Emerging; fewer FDA-cleared systems; still opportunity for entry

AMD/Retinal Disease Diagnosis: - US AMD patients: 2M; Annual diagnosis need: 500K (new diagnoses) - Revenue per diagnosis: $60-120 - TAM: $30-60M annually (diagnosis); $200-400M (treatment optimization) - Status (June 2030): Fragmented; opportunity for specialized players

Surgical Planning (IOL selection, LASIK, refractive surgery): - US cataract surgeries: 2-3M annually; LASIK: 600K annually - Revenue per surgical case optimization: $200-500 - TAM: $600-1,500M annually - Status (June 2030): Growing; less crowded than diagnostic market; higher margins

Total Addressable Market (Ophthalmology AI, US only): $1.2-2.5B annually (2030 estimate)

This was smaller than VC hype suggested pre-2028, but large enough to support 5-10 successful companies.

VII. THE ACQUISITION/EXIT LANDSCAPE (JUNE 2030)

Strategic Acquirers

By June 2030, the primary acquirers of successful ophthalmology startups were:

1. Large Medical Device Companies:
2. Bausch + Lomb: Acquired RetinalGenix (2029), pursuing Autonomous partnership
3. Alcon: Acquired RxSight (2029), pursuing partnerships with Comet AI

4. Johnson & Johnson: Acquired several small imaging startups; pursuing EyeThink partnership

5. Tech Giants:

6. Google Health: Built internal ophthalmology AI team; acquired small startups (2028-2029); pursuing partnerships with Autonomous
7. Amazon: Launched ophthalmology initiatives; pursuing acquisitions for telehealth/remote diagnosis

8. Apple: Building Health features including vision; potential acquirer of AI refraction companies

9. Healthcare Platforms:

10. UnitedHealth: Acquired small telehealth ophthalmology startups (2029)
11. CVS Health: Pursuing AI diagnostic acquisition for retail pharmacy rollout

Exit Valuations & Outcomes (2029-2030)

Successful exit (acquisition/IPO-track): - Autonomous Health: Series B valuation $800M → projected Series C/D valuation $1.8-2.4B; strategic partnership with Bausch + Lomb announced (2030) - EyeThink: Series B valuation $650M → projected Series C $1.2-1.8B - Retinal AI: Series A $85M → Series C pending (estimated $400-600M)

Down-round/distressed acquisition: - Comet AI: Series B valuation $300M → Series C down-round $120M; seeking strategic buyer - RetinalGenix: Pre-acquisition valuation $550M → Alcon acquisition ~$180M (implied 67% markdown)

Realistic IPO prospects: By June 2030, 0 pure AI ophthalmology companies had gone public; IPO prospects seemed unlikely unless growth accelerated. More likely: strategic acquisition by large medical device or tech company.

VIII. GEOGRAPHIES & MARKET ENTRY (US vs. INTERNATIONAL)

US-First Positioning: The Winning Strategy

By June 2030, all successful companies pursued US-first commercialization: 1. FDA clearance first (De Novo or 510(k)) 2. US large group adoption (proof-of-concept) 3. Payer reimbursement (CMS, commercial insurance) 4. International expansion (CE Mark, other regulatory approvals) as Phase 2

Why US-first won: - Clearer regulatory pathway (FDA known entity, timelines predictable) - Larger market (300M vs. 67M in Canada/UK/Australia combined) - Better payer reimbursement (CMS willing to pay for innovations) - Easier exit (US-based acquirers, exit paths)

International Expansion (2030 onwards)

By June 2030, successful US companies were beginning international expansion: - Canada: Regulatory approval easier; adoption faster; same payer dynamics as US - UK/Australia: More conservative adoption; fewer reimbursement pathways; served by smaller, local competitors

IX. THE WINNING FOUNDER PROFILE (JUNE 2030)

Based on successful exits and surviving companies, the profile of winning founders includes:

1. Healthcare pedigree: PhD or MD/residency training in ophthalmology or related field (not pure data scientists)
2. Regulatory expertise: Co-founder or early advisor with FDA experience
3. Customer intimacy: Relationships with ophthalmologists, large group owners, hospital systems
4. Capital discipline: Bootstrap or Series A only until achieving clear market validation
5. Clinical evidence obsession: Invested in RCTs, published validation studies before scaling
6. US regulatory focus: Pursued FDA clearance as first major milestone
7. Specific problem focus: Targeted one clinical indication deeply (not "general ophthalmology AI")

Founders who DIDN'T survive this profile: - PhD-only data scientists without clinical advisors - Founders pursuing international-first positioning - Those bootstrapping without early institutional capital - Founders with general-ophthalmology ambitions instead of specific niches

X. OPPORTUNITIES FOR NEW FOUNDERS (JUNE 2030)

Where New Capital Can Play

By June 2030, despite the 2029 crash, several opportunities remained:

High-opportunity areas: 1. AI for neuro-ophthalmology: Underexplored; limited competition; high clinical value 2. AI for pediatric ophthalmology: Strabismus planning, refractive error management 3. AI-powered telehealth integration: Not yet saturated; rural market growing 4. Smart contact lens technology + AI: Emerging; capital-intensive but defensible 5. AI for drug development: Using AI to optimize new ophthalmic therapeutics (less direct clinical adoption barriers)

Lower-opportunity areas (saturated): 1. Diabetic retinopathy AI (3-5 FDA-cleared competitors) 2. General retinal disease diagnosis (overcrowded) 3. Non-regulated AI refraction (regulatory risk) 4. Glaucoma screening (getting crowded; 2-3 competitors)

Capital Availability & Expectations (2030+)

• Series A: Still available for companies with FDA approval or clear regulatory pathway; typical round $25-50M
• Series B: Only for companies with $5M+ run-rate revenue and large customer wins; typical round $50-150M
• Later rounds: Reserved for high-growth companies with clear path to $100M+ revenue
• Down-rounds: Common; expect 20-30% dilution in Series B/C 2029-2032

XI. THE LONG-TERM FORECAST FOR OPHTHALMOLOGY FOUNDERS

2031-2035 Landscape

By June 2030, the pattern was clear for what ophthalmology AI/innovation would look like 2031-2035:

1. Consolidation around 3-5 large platforms: Autonomous Health, EyeThink, Retinal AI, plus Google/Amazon/Apple health initiatives
2. Specialty dominance: Winners in specific clinical areas (neuro, pediatric, etc.) rather than "general" systems
3. Surgical focus: Surgical planning/optimization less disrupted than diagnosis; sustained opportunity
4. Retail/consumer disruption: AI refraction, smart contacts, direct-to-consumer eyewear will continue; regulatory battles ongoing
5. Telehealth integration: Continued growth for remote diagnosis platforms, especially serving underserved areas

END OF MEMO

The 2030 Report Global Intelligence Crisis Series | Confidential | June 2030